HLB Pharmaceutical (Korea) Today
| 047920 Stock | KRW 17,100 7,300 29.92% |
PerformanceVery Weak
| Odds Of DistressLow
|
HLB Pharmaceutical is trading at 17100.00 as of the 23rd of March 2025, a 29.92 percent decrease since the beginning of the trading day. The stock's open price was 24400.0. HLB Pharmaceutical has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, develops peptide drugs in South Korea. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju, South Korea. HLBPHARMA is traded on Korean Securities Dealers Automated Quotations in South Korea. The company has 13.85 M outstanding shares. More on HLB Pharmaceutical Co
Moving against HLB Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
HLB Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. HLB Pharmaceutical's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding HLB Pharmaceutical or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Hae Park |
| Business Concentration | Pharmaceuticals, Healthcare (View all Sectors) |
HLB Pharmaceutical Co (047920) is traded on KOSDAQ in Korea and employs 14 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 173.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate HLB Pharmaceutical's market, we take the total number of its shares issued and multiply it by HLB Pharmaceutical's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. HLB Pharmaceutical operates under Healthcare sector and is part of Pharmaceuticals industry. The entity has 13.85 M outstanding shares.
HLB Pharmaceutical Co has accumulated about 6.64 B in cash with (1.32 B) of positive cash flow from operations.
Check HLB Pharmaceutical Probability Of Bankruptcy
Ownership AllocationThe market capitalization of HLB Pharmaceutical Co is W173.79 Billion. HLB Pharmaceutical shows considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check HLB Ownership Details
HLB Pharmaceutical Risk Profiles
Although HLB Pharmaceutical's alpha and beta are two of the key measurements used to evaluate HLB Pharmaceutical's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.36 | |||
| Standard Deviation | 5.84 | |||
| Variance | 34.15 | |||
| Risk Adjusted Performance | (0.03) |
HLB Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in HLB Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Valuation Now
Equity ValuationCheck real value of public entities based on technical and fundamental data |
| All Next | Launch Module |
HLB Pharmaceutical Corporate Management
Elected by the shareholders, the HLB Pharmaceutical's board of directors comprises two types of representatives: HLB Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HLB. The board's role is to monitor HLB Pharmaceutical's management team and ensure that shareholders' interests are well served. HLB Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HLB Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JongBin Kim | Managing Director | Profile | |
| Dong Lee | Assistant Managing Director | Profile | |
| Jeong Yoo | Assistant Managing Director | Profile | |
| Jae Noh | Internal Auditor | Profile | |
| DongYeop Lee | Managing Director | Profile | |
| Jeong Yoon | Director | Profile |
Other Information on Investing in HLB Stock
HLB Pharmaceutical financial ratios help investors to determine whether HLB Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLB with respect to the benefits of owning HLB Pharmaceutical security.